Epstein-Barr virus (EBV),
Introduction
Cellular immunity is critical for virus-associated malignant disease since specific T lymphocytes recognize viral antigens. Adoptive immunotherapy with cytotoxic T lymphocytes (CTLs) has been used successfully to treat Epstein-Barr virus (EBV)-associated malignant disease (1) (2) (3) (4) . This could be obtained using the antigen presenting capacity of dendritic cells (DCs) and priming T lymphocytes (5, 6) . Many immunotherapy protocols in human cancer have shown limited efficacy, implying research for improved strategies. It has been demonstrated that DCs modification such as protein load can be successfully applied in tumor immunotherapy. DCs loaded with protein can promote cellular immunity both in experimental animal models and humans (8) (9) (10) (11) . Optimal antigen loading strategies provide epitopes presented by both MHC class I and class II leading to a diverse immune response in which many clones of cytotoxic T cells (CTLs) and CD4 + T cells are involved (12) (13) (14) . EBV is associated with virtually all cases of undifferentiated nasopharyngeal carcinoma (NPC) and has been classified as a group I carcinogen (15) (16) (17) (18) . In addition to its potential role in the pathogenesis of NPC, EBV also provides a possible target for immunotherapy of NPC, since a limited number of viral genes are expressed in the neoplastic cells, including EBNA1, LMP1 and LMP2 (16, 17, 19, 20) . Although EBNA1 appears to be an immunogen for reactivating EBNA1-specific CD4 + T cell clones, the majority of such clones fail to recognize lymphoblastoid B cell lines (LCL) target cells (21) . LMP1 has been confirmed to be consistent with its ability to transform rodent fibroblasts, and its target epitopes recognized by virus-specific CTL are easy to mutate (22) . LMP2A, however, is considered a promising target antigen for developing immunotherapy. LMP2 epitopes are conserved among viral strains and contain HLA-restricted CTL target epitopes which can elicit strong specific CTL responses (23) (24) (25) .
Previous studies of immune responses in NPC patients had demonstrated a generalized immunosuppression in these individuals. NPC patients possessed CTL precursors specific for EBV-LMP2 and EBV-specific T cell responses were detectable in patients, albeit at lower levels than in healthy controls (26, 27) . The point was whether they included responses to those viral proteins expressed in the tumor. Therefore, it was very important to correct this low CTL-response status and elicit an effective EBV-specific CTL in NPC patients as one of the key immunotherapeutic strategies (28) (29) (30) .
Here we examined the possibility of a CTL-based therapy for NPC by DCs loaded with EBV-LMP2A. First, we had constructed EBV LMP2A gene recombinant retrovirus vector and established L929 cell line stably expressing LMP2A. Purified LMP2A protein was obtained from eukaryotic expression. Second, dendritic cells from blood samples of healthy Chinese virus carriers were induced and used to be loaded with EBV-LMP2A purified protein. The Agpresenting function and CTL cytotoxicity were then assessed. The research provides experimental and theoretical basis for our further studies on DC-based immunotherapy.
Materials and Methods

Cell lines and blood donors
Human embryo kidney 293T, murine fibroblast NIH3T3 and L929 cell line were cultured in RPMI 1640 medium (GIBCO, Grand Island, NY) supplemented with 10% heat-inactivated fetal calf serum (FCS, GIBCO), 2 mmol/L L-glutamine, 100 IU/ml penicillin, 100 μg/ml streptomycin, and 1 mmol/L sodium pyruvate. Cord blood mononuclear cells (CBMCs) were cultured in RPMI 1640 medium supplemented with 10% FCS. The donors were healthy individuals without evidence of acute EBV infection. Sera from donors were positive for IgG antibodies to the EBV protein EBNA-1 and viral capsid antigens (titer equal to or higher than 1:10) analyzed by indirect immunofluorescence (IIF, Euroimmun, Germany).
LMP2A expression in eukaryote cell line L929
Retroviral vector stocks were produced according to the three-plasmid transient-transfection protocol described by Soneoka et al (31) . Briefly, two auxiliary viral vectors pHIT456, pHIT60, and the appropriate recombinant retroviral expression vector pSIV-1/LMP2A vector were transfected into 293T cells using lipofectAMINE2000. The supernatants containing recombinant retrovirus were harvested to infected L929 cells. L929/LMP2A cells were screened for LMP2A expression by flow cytometric analysis and Western blotting. In order to obtain purified LMP2A protein, L929/LMP2A cells were lysed and then loaded onto a His-Bind Ni 2+ column (pH = 8.0) (Merck, Germany) and tested for LMP2A expression by Western blotting.
Flow cytometric and confocal analysis
Expression of LMP2A and DC surface markers was assessed by flow cytometry or confocal analysis. Rabbit polyclonal antibody LMP2A (kindly provided by Dr. JM Middeldorp, Netherland) was used for detection of LMP2A expression. For DC immunophenotyping, DCs were washed with PBS and incubated with anti-HLA-DR, anti-CD80, anti-CD1a, anti-CD83, anti-CD14, and anti-CD86 anti-bodies conjugated with phycoerythrin (PE) or fluorescein isothiocyanate (FITC) (BD PharMingen, San Diego, CA) for 30 min at 4°C. Flow cytometric analysis was performed with a FACScan, using LYSIS II software (BD Biosciences). For detection of the distribution of LMP2A on DCs after loaded, FITCconjugated goat anti-rabbit IgG was used as secondly Abs, and DCs were scanned with confocal microscope.
Western blotting
Samples were run out on SDS-polyacrylamidegels, then were transferred onto nitrocellulose, and blocked in 5% skim milk powder in Tris-buffered saline containing 0.05% Tween 20 (TBST). Blots were incubated with primary antibody LMP2A in TBST with 5% bovine serum album overnight at 4°C. Blots were then rinsed triple in TBST followed by incubation with an alkaline phosphatase (AP)-conjugated secondary antibody, goat anti-rabbit IgG for 1 h at room temperature. Blots were rinsed several times in TBST and stripped with DAB.
Generation of monocyte-derived DCs and LMP2A loading
Human PBMCs were obtained from healthy EBV-positive donors by Ficoll density centrifugation. Monocyte-derived DCs were generated essentially as previously described (32) . In brief, monocyte-derived DCs were harvested after 5 to 7 days of culture in the presence of 200 ng/ml rhGM-CSF and 100 ng/ml rhIL-4 (Peprotech, England). Then purified LMP2A protein was incubated with immature DCs at different concentrations for 2 h in complete medium before maturation. Mature DCs were obtained by adding 200 ng/ml TNF-α to medium culture at day 6 as previously described. The surface level of loaded LMP2A on DCs was measured by flow cytometry.
Mixed leukocyte reaction (MLR) and T cell proliferation assay
Lymphocyte cultures were conducted in triplicate in 96-well flat bottom plates. Responder T cells were isolated from CBMCs by the method of sheep-erythrocyte-rosette formation and added at the concentration of 2 × 10 5 cells/well. Stimulator cells (DCS-LMP2A or DCs) were pretreated with 25 μg/ml mitomycin C for 45 min at 37°C, washed three times with RPMI 1640, then added at different doses ranging from 1 × 10 4 to 1 × 10 3 cells/well. The culture medium used was HEPES-buffered RPMI 1640 with 10% heat-inactivated FBS, and 50 μM β-mercaptoethanol. The proliferation was measured by adding 3 H-thymidine for the last 16 h of a 4-day culture period. T cell proliferation was expressed as counts per minute (cpm) and also presented as the mean stimulation index (SI). SI was calculated by the following formula: SI = (cpm infected -cpm background ) / (cpm uninfectedcpm background ).
In T cell proliferation assay, responders were changed into autologous CD4 + and CD8 + T cells purified by positive selection with anti-CD4 + or CD8 + -coupled Dynabeads (Dynal, Lake Success, NY), median purity of which was determined by flow cytometric analysis and were routinely > 95%. Immature DCs were cocultured for 2 h at 37°C with 40 μg/ml purified LMP2A protein (concentration determined by FACS). TNF-α (200 ng/ml) was added to induce DC maturation and IL-2 (10 IU/ml) to support the proliferation of purified T cells.
Generation of EBV-LMP2A specific CTLs
To obtain effector CTLs, CD8 + T lymphocytes purified by positive selection with anti-CD8 + -coupled Dynabeads were repeatedly stimulated with autologous DCs loaded with LMP2A. In brief, DCs loaded with purified LMP2A protein were used as stimulatory cells while autologous purified CD8 + T cells were used as responders, which were generated from PBMCs of healthy HLA-A*0201 donors. Loaded DCs (10 5 /well) were cultured in 24-well plates (Costar) with 10 6 T cells in a final volume of 1 ml. The medium was supplemented with 10% AB serum, TNF-α (200 ng/ml in week 1), and IL-2 (10 IU/ml in weeks 2 and 3). T cells were restimulated weekly for additional 2 weeks with loaded or unloaded DCs. Six days after the last stimulation, cells were harvested and the cytotoxic activity was tested. Control T cells were grown under the same culture conditions in the presence of IL-2 without protein stimulation.
Cell-mediated cytotoxicity assay HLA-matched CTLs were used as effector cells. Autologous DCs loaded with HLA-A2 binding LMP2A peptides CLGGLLTMV(CLG) (24, 33, 34) , autologous DCs, autologous EBV-transformed LCLs and K562 cells were used separately as target cells. The cytolytic activity of CTLs was tested in a 6 to 16-hour LDH release assay performed in triplicate per condition, using 5 × 10 3 target cells per well in U-bottom, 96-well microplates. Cytotoxicity was quantitatively determined by the release of the cytosolic enzyme, lactate dehydrogenase (LDH) in culture supernatants (35) . Specific lysis was calculated by the following formula: specific lysis (%) = (experimental release -target spontaneous release) / (target maximum -target spontaneous release) × 100%.
Statistical analysis
The data were expressed as mean ± standard deviation and analyzed by SPSS10.0 software. The Student's t test was used to test for significance in each set of values, and p < 0.05 was considered as statistically significance.
Results
Expression and purification of LMP2A protein
Full-length cDNA encoding EBV LMP2A (exons 1-8) was cloned into retroviral expression plasmid pSIV-1 ( Figure  1A ). Positive 293T clones were obtained after being co-transfected with pSIV-1/LMP2A, pHIT456 and pHIT60 by lipofectAMINE2000 to produce retroviral virus, which yielded a titer of 5 × 10 5 infectious particles/ml. L929 cell line stably expressing LMP2A was established after infected with recombinant retrovirus. Transduction rate was 91.3% determined by flow cytometry ( Figure 1B ). An expected specific protein (about 54 kDa) was detected by Western blot which indicated that LMP2A was successfully expressed in the infected L929/LMP2A ( Figure 1C ). The lysate of L929/LMP2A was purified, and 300 μg/ml purified LMP2A proteins were obtained. The peak fraction was confirmed by anti-LMP2A Western blotting.
Evaluation of LMP2A protein loaded onto DC
We evaluated the effects of protein loading on the expression of DC surface markers. Immature DCs were loaded with purified LMP2A protein at different concentrations of 0 μg/ml, 10 μg/ml, 20 μg/ml, 40 μg/ml and then induced DC maturation. The efficiency of LMP2A protein loading onto DC was evaluated by flow cytometric analysis of LMP2A expression (Figure 2A ). The expression of LMP2A did not reach the detectable level on normal mature DCs, however, more than 80% of the DCs expressed LMP2A after coculture with 40 μg/ml LMP2A protein. The ability of DC to capture antigen was also confirmed by confocal microscope ( Figure  2B ).
LMP2A-loading does not affect DC phenotype and function
Monocyte-derived DCs were stained with specific mAbs to assess the expression of typical DC surface markers. DCs generated with this procedure were defined as immature, since they expressed little or no CD83 (data not shown), a marker usually observed on mature DCs. After incubation with TNF-α for 48 h, DCs were induced morphological and phenotypical changes. The results of flow cytometric analysis on these mature DCs indicated an increase in the intensity of expression of all markers except CD14. The loaded DCs showed a pattern and intensity of marker expression similar to that observed in mature DCs ( Figure 3A) , clearly indicating that loading protein LMP2A had no effect on phenotype and surface markers of DCs.
To assess the ability of DCs-LMP2A to stimulate an MLR, allogenic T cells were isolated and incubated with DCs-LMP2A or DCs separately at different cell concentrations. Our data indicated that as few as 1000 DCs-LMP2A were able to stimulate a significant MLR. Unloaded DCs were also able to stimulate MLRs, but the responses were much lower (p < 0.05) ( Figure 3B ). These results indicated that although the both DC populations had ability to stimulate MLR, DCs-LMP2A were more potent than unloaded DCs.
DCs loaded with LMP2A induces EBV-LMP2A specific CTLs
To assess DCs' Ag-presenting ability and EBV-LMP2A specific immune response, an autologous T cell proliferation assay in vitro was performed. Immature DCs were loaded with LMP2A protein, sorted based on CD1a expression (purity > 90%), and cocultured with purified autologous T cells (purity > 90%) in the presence of TNF-α, which induces maturation of both loaded and unloaded DCs as determined by CD83 expression (data not shown). As shown in Figure  4A , the proliferative responses of CD4 + T and CD8 + T cells to DCs loaded with LMP2A were significantly increased compared to cells cocultured with DCs.
To determine if the generated LMP2A-specific CTLs had cytotoxic activity, CTLs were tested against a panel of targets in cytotoxicity assays. LMP2A-specific CTLs were generated from healthy, HLA-A*0201-positive, EBV-seropositive healthy donors by stimulating CD8 + T cells with autologous LMP2A-expressed DCs. As shown in Figure 4B , LMP2A-specific CTLs lysed autologous DCs loaded with HLA-A2-restricted LMP2A peptide CLGGLLTMV (CLG), whereas DCs alone or with an unrelated K562 cells were resistant to killing. LMP2A-specific CTLs were also tested for their ability to lyse autologous LCLs. It's found that LMP2A-specific CTLs had the highest cytotoxicity against DCs loaded with CLG peptide and had a 2-fold higher cytotoxicity in comparison with LCLs, which indicated the difference in LMP2A expression level between these two target cells.
Discussion
The association of a great expansion of the spectrum of tumors with EBV has been firmly established, including Burkitt's lymphoma (BL), Hodgkin's disease (HD), undifferentiated NPC, and various T-cell lymphomas (16, 36, 37) . To date, conventional approaches for the treatment of EBVrelated malignancies are often not curative or associated with serious complications. New immunotherapeutic strategies, such as adoptive transfer of CTLs or mAbs, may be effective if the tumor cells express immunodominant proteins (25, 27, 38) . HD, BL, and NPC cancers appeared to be less susceptible to immunotherapeutic intervention, presumably due to the expression of a more restricted array of subdominant EBV-encoded epitopes derived from latent proteins (EBNA1, LMP1, and LMP2) (19, 20) . LMP2 expression was observed in the majority of EBV-associated NPC tumors. Although it was considered as subdominant Ags, they provided targets for immunotherapeutic approaches (19, 23, 24, 34) .
LMP2-specific T cells are present in the peripheral blood of patients with EBV-positive NPC. This implies that these malignancies are able to develop despite the presence of circulating tumor-specific T cells. Secretion of immunosuppressive chemokines and cytokines and the presence of regulatory T cells at the tumor site may contribute to this escape from immune surveillance (21) . Immunotherapeutic strategies that enhance the LMP2-specific immune response may overcome this immunosuppressive environment. LMP2-specific T cells can be actively boosted in vivo by vaccination with LMP2A protein loading. Alternatively, LMP2-specific T cells can be removed from the immunosuppressive environment and expanded ex vivo. The development of protocols capable of promoting the induction and main tenance of anti-EBV-reactive T cells is therefore of significant clinical merit. We would further evaluate the efficacy of DC-based vaccination.
DCs are the most potent antigen-presenting cells (APCs) and appear optimally capable of initiating and modulating the T-cell immune response (7, 8, 39) . All kinds of modified DC approaches have been investigated to be applied in antitumor responses. It has been shown that protein-loaded DCs contain viral antigens and have antigen presentation capability that makes them become a potentially attractive vector for trigger T-cell antitumor responses (9) (10) (11) (12) 40) . However, there is no report about immunotherapy with specific CTL in NPC patients induced by DCs loaded with LMP2A protein.
In this study, we used purified LMP2A protein from the lysate of infected L929/LMP2A cells to load onto DCs and analyzed the effect on the phenotype and function of loaded DCs. Due to the ability to perform many of the posttranslational modifications and correctly fold of eukaryote expression system, EBV-LMP2A was expressed in eukaryote cell line L929 and the structures of expressed LMP2A protein were more familiar with natural conformations.
In this context, DCs represent attractive vectors for tumor immunotherapy because they can capture defined tumor target antigen and present these antigens to elicit or recall the T-cell immune responses. We explored immunotherapy of NPC by the method of DCs loaded with LMP2A protein. Such approach offers new possibilities for LMP2A delivery to DCs because the use of complete protein as a source of Ags should provide both MHC class I and class II epitopes leading to a diverse immune response involving many clones of CTLs and CD4 + T cells, the latter being able to recruit other effectors such as macrophages and eosinophils, and stable and durable expression of peptide-MHC complexes sufficient for the priming of naїve T cells.
This study focused on the ability and efficiency of DCs loaded with the LMP2 protein in vitro. We chose to initially evaluate whether the protein load can affect phenotype and function of human DCs. As we know, PBMC-derived immature DCs have potent ablity to migrate, ingest and dispose antigens, while mature DCs secrete large quantities of inflammatory chemokines, up-regulate the expression of constitutive chemokines and chemokine receptors CXCR4 and CCR7 to attract resting T cells and stimulate T cell maturation and polarization, switch on all kinds of immune response. In this study, PBMCs were isolated from heparinized whole blood of healthy volunteer donors and immature DCs were cultured for 5 days. After these immature DCs ingested purified EBV-LMP2A protein at different concentrations, we added TNF-α as an auxiliary stimulatory signal on mature DCs and chemotaxis. Loaded imDC remained phenotypically immature, as determined by low expression levels of CD83, antigen-presenting molecules. The antigen loading process did not promote DC maturation. Optimal phenotypic and functional maturation of DCs occurred when DCs were loaded with LMP2A and concomitantly treated with a maturational cytokine, resulting in strong augmentation expression of CD83 and MHC II and coexpression of CD80, CD86, and CD40 on DCs. In addition, 40 μg/ml LMP2A protein revealed the appropriate dose, resulting in more than 80% of the DCs expressed LMP2A. The ability of DCs capturing antigen was also observed by confocal analysis. Thus, EBV-LMP2A protein load neither promoted nor hindered our ability to generate mature DCs. Meanwhile, to detect stimulatory capacity of the loaded DCs to naïve T cells, an allogenic MLR was performed. The results showed that LMP2A-loaded DCs were stimulated MLR better than unloaded DCs did, which indicated LMP2A loading did not result in DC dysfunction and LMP2A-loaded DCs could be used as APCs in immune response. We also observed DCs presenting LMP2A to autologous T cells by measuring cell proliferation. As shown in our data, loaded DCs have the ability to prime antigenspecific CD4 + and CD8 + T cell proliferation. High cytotoxicity of LMP2A-specific CTLs could be elicited by autologous DCs loaded with HLA-A2-restricted LMP2A peptide.
In conclusion, the results above suggested that LMP2A can be expressed stably in L929 cell line and purified LMP2A protein was obtained. No significant changes in the surface markers and the cytomorpholosis of DCs during protein loading. DCs loaded with EBV LMP2A protein may allow for the generation of in vitro vaccines capable of promoting EBV-specific T cells. These data encourage efforts to the potential clinical application of such EBVbased systems for the treatment or the prevention of EBVrelated malignancies. 
